Flash-Player installieren

» Flash-Player installieren
» Watch video in bigger size

ScheBo® · Biotech AG
Netanyastrasse 3
35394 Giessen

Phone +49 (0)641 / 4996-0
Fax +49 (0)641 / 4996-77

Company profile

ScheBo® Biotech AG is an innovative biotech company that is active in the field of development, production and marketing of diagnostics.

The manufacturing of our leading products is matched exactly to satisfy of our customers.

ScheBo® Biotech AG was founded by the biochemists and molecular biologists Ursula Scheefers-Borchel, Ph.D., and Hans Scheefers, Ph.D.

Continuous innovation, strong customer focus and creative problem solving have made ScheBo® Biotech AG a worldwide leading manufacturer of unique products. We invite you to convince yourselves of the advantages of ScheBo® Biotech AG. Come and see!

ScheBo® Biotech AG
Netanyastrasse 3 / 35394 Giessen / Germany
Phone: +49-(0)641-4996-0 /Fax: +49-(0)641-4996-77
eMail: schebo@schebo.com / Internet: www.schebo.com

Board of Executives of ScheBo® Biotech AG:
Ursula Scheefers-Borchel, Ph.D.
Hans Scheefers, Ph.D.
René M. Kröger, Ph.D.

Foundation (year): 1989

Areas of Activity: VD-Diagnostics, Drug development

Biological Patents:
ScheBo® BiotechAG holds many national and international patents in the above fields

External Collaborations:
ScheBo® Biotech AG has academic alliances with several universities and university hospitals in Europe, USA, Japan, England, Italy, Israel and Canada.

  • ScheBo® Biotech UK Ltd., founded: 1999
  • ScheBo® Biotech USA Inc., founded: 2001

The company:

  • is specialiced in the manufacturing of monoclonal antibodies against a variety of antigens, the development of routine test procedures (e.g. ELISA systems, biosensors) and the identification and isolation of target proteins,
  • is completely privately funded and hence independent,
  • operates internationally,
  • offers innovative products which have world-wide a unique position in the field of clinical diagnostics.

World-wide Innovations:

R&D and manufacturing led to the successful launch and sales of the following products:
  • ScheBo® Pancreatic Elastase 1 Stool Test
    (launched in 1993)
  • ScheBo® Pancreatic Elastase 1 Serum Test
    (launched in 1994)
  • ScheBo® Tumor M2-PK™ EDTA Plasma Test*
    (launched in 1998)
  • ScheBo® Elastase Canine Test
    (launched in 1999)
  • ScheBo® Brainostic™ Western Blotting Test
    (launched in 2000)
  • ScheBo® Quick-Prep®
    (launched in 2002)
  • ScheBo® Tumor M2-PK™ Stool Test Laboratory*
    (launched in 2003)
  • ScheBo® Tumor M2-PK™ Stool Test Pharmacy*
    (launched in 2003)
  • ScheBo® Pancreatic Elastase 1 Stool Test (fast)
    (launched in 2004)
  • ScheBo® Brainostic™ GFAP ELISA
    (launched in 2004)
  • ScheBo® Pancreatic Elastase Serum Test (fast)
    (launched in 2005)
  • ScheBo® M2-PK Quick™ -Test (lateral flow test)
    (launched in 2007)
  • ScheBo® 2in1 Quick™ -Test (lateral flow test)
    (launched in 2012)

*Info: www.metabolic-database.com
Open file in new window
Link to the VBU Guide of German Biotech R & D Companies!

Multicenter Study: Newest data on the M2-PK test published in journal "Gut and Liver"
Korean Scientists have published the very newest data on the M2-PK test in the renowned specialist journal ‚Gut and Liver‘.
New ScheBo® · Pancreas Elastase 1 Quick™ Canine test
The stool test for the fast and reliable diagnosis/ exclusion of Exocrine Pancreatic Insufficiency in canine is
… now also available as a rapid test
New ScheBo® · Pancreas Elastase 1 Quick™ test
Faecal Pancreatic Elastase 1
The Gold Standard for Non-Invasive Exocrine Pancreatic Function Testing
… now also available as a rapid test
2in1 Colorectal Cancer Screening Test
New innovative combined rapid test to simultaneously detect the enzyme biomarker M2-PK and human haemoglobin for improved colorectal cancer screening.
Meta-analysis published of faecal M2-PK in colorectal cancer screening
Authors conclude that "We recommend faecal M2-PK as a routine test for CRC screening".
Biomarker ′M2-PK′ Identified as Key Enzyme in Cancer Diagnosis and Therapy
Ground Breaking Findings on Understanding Cancer Published in ′Science′
Video: Focus 2010 lecture on M2-PK
The high sensitivity (c.80%) and high specificity (>90%) of the M2-PK stool test for colorectal cancer screening and detection, plus benefits for patients, laboratories and doctors, was presented at Focus 2010
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.